Get started
Author

Pierre Foidart

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
2020 · Florence Coussy, Rania El-Botty, et al. · Science Translational Medicine · 146
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
2018 · Elisabetta Marangoni, Cécile Laurent, et al. · Clinical Cancer Research · 63
PDF
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy
2018 · Pierre Foidart, Cassandre Yip, et al. · Clinical Cancer Research · 53
Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3
2024 · Marco Seehawer, Zheqi Li, et al. · Nature Cell Biology · 48
Midkine as a driver of age-related changes and increase in mammary tumorigenesis
2024 · Pengze Yan, Ernesto Rojas Jimenez, et al. · Cancer Cell · 47
MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases
2019 · Cassandre Yip, Pierre Foidart, et al. · International Journal of Molecular Sciences · 39
PDF
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
2023 · Maša Alečković, Zheqi Li, et al. · Molecular Cancer Therapeutics · 19
PDF
MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib
2017 · Cassandre Yip, Pierre Foidart, et al. · British Journal of Cancer · 17
PDF
Breast cancer prevention by short-term inhibition of TGFβ signaling
2022 · Maša Alečković, Simona Cristea, et al. · Nature Communications · 14
PDF
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
2024 · Benedetto DiCiaccio, Marco Seehawer, et al. · Cell Reports · 12
Whole-genome doubling drives immune evasion by silencing antigen presentation
2026 · Pierre Foidart, Zheqi Li, et al. · Cancer Cell · 3
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression
2026 · Triet Minh Bui, Ernesto Rojas Jimenez, et al. · Cancer Cell · 2
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer
2026 · Ernesto Rojas-Jimenez, Triet M. Bui, et al. · Proceedings of the National Academy of Sciences · 2
Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4
2026 · Chen Chu, Shanshan Zheng, et al. · Molecular Cell · 1
PDF
HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al. · Cancer Discovery · 1
[Diagnosis of anemia associated with alcoholic cirrhosis].
2019 · V Delmotte, P Foidart, et al. · PubMed · 1
Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer
2026 · Gilles Colin, Sylvie Streel, et al. · Nature Reviews Gastroenterology & Hepatology
Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination
2026 · Jun Nishida, Marco Seehawer, et al. · Proceedings of the National Academy of Sciences
Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response
2026 · Zheqi Li, Amatullah Tawawalla, et al. · Nature Communications
PDF
Patients’ and specialist physicians’ perspectives on the use of polygenic risk scores in clinical practice: a cross-sectional study
2026 · Arina Nostaeva, Juliette Beuriot, et al. · BMC Medical Genomics
Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al.
Supplementary Table S1 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al.
Supplementary Table S7 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al.
Supplementary Table S8 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al.
Supplementary Figures S1-S9 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
2026 · Marie-Anne Goyette, Christopher Graser, et al.
Works count: 101
Citation count: 468
H-index: 10
I10-index: 10
Year
Topic
Type